STE

STERIS (STE) reported Healthcare segment sales growth of 8% to $1.05 billion in fiscal Q1, driven by services and consumables, while AST segment grew 6% to $297.6 million with improved growth expected in H2. The company faces margin pressures from $14 million in tariff costs and inflation, though strong demand persists in healthcare and life sciences markets. Management maintains fiscal 2027 EPS guidance at $11.12 with projected 7.3% revenue growth.

STERIS plc announced a definitive agreement to acquire Xodus Medical, a specialty surgical products company, for $2.1 billion (net purchase price ~$1.8 billion after tax benefits). The acquisition is expected to close by December 31, 2026, and includes potential earnout consideration up to $150 million.

Xodus Medical generated approximately $245 million in annual revenue for 2026 with $135 million in adjusted EBIT. STERIS expects the transaction to be accretive to top-line growth, margins, and adjusted earnings.